| Brown JT et al. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin Pharmacol Ther. 2015 Dec 11 [Epub ahead of print]. | Pharmacokinetic | 2015-12 | |
| Bishop JR et al. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015;25:548-54. | Cohort | 2015-11 | |
van de Bilt MT et al. Cytochrome P450 genotypes are not associated with refractoriness to antipsychotic treatment. Schizophr Res. 2015;168:587-8.
| Case Control | 2015-10 | |
| Walden LM et al. Physicians' opinions following pharmacogenetic testing for psychotropic medication. Psychiatry Res. 2015;229:913-8. | Observational | 2015-10 | |
| Fijal BA et al. CYP2D6 predicted metabolizer status and safety in adult patients with attention-deficit hyperactivity disorder participating in a large placebo-controlled atomoxetine maintenance of response clinical trial. J Clin Pharmacol. 2015;55:1167-74. | Post hoc analysis | 2015-10 | |
| Winner JG et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin. 2015;31:163343. | Prospective Cohort | 2015-09 | |
| Tomaz PR et al. CYP2B6 rs2279343 polymorphism is associated with smoking cessation success in bupropion therapy. Eur J Clin Pharmacol. 2015;71:106773. | Retrospective Cohort | 2015-09 | |
| Uckun Z et al. The impact of CYP2C19 polymorphisms on citalopram metabolism in patients with major depressive disorder. J Clin Pharm Ther. 2015;40:672-9 | Case Control | 2015-09 | |
| Zhan YY,et al. Effect of CYP2D6 variants on venlafaxine metabolism in vitro. Xenobiotica. 2015 Sep 25 [Epub ahead of print]. | PK/PD | 2015-09 | |
Brown JT et al. Atomoxetine pharmacogenetics: associations with
pharmacokinetics, treatment response and tolerability. Pharmacogenomics.
2015;16:1513-20. | Review | 2015-08 | |
| Probst-Schendzielorz K et al. Effect of cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors. Expert Opin Drug Metab Toxicol. 2015;11:1219-32. | Review | 2015-08 | |
| Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci. 2015;13:150-6 | Randomized Controlled Trial | 2015-08 | |
| Peters ME et al. Citalopram for the treatment of agitation in Alzheimer dementia: genetic influences. J Geriatr Psychiatry Neurol. 2015 Aug 23 [Epub ahead of print]. | Retrospective Cohort | 2015-08 | |
| Garmén AK et al. Extreme duration of diazepam-associated sedation in a patient with alcohol delirium and CYP2C19 polymorphisms. J Clin Psychopharmacol. 2015;35:475-7. | Case Report | 2015-08 | |
| Haufroid V et al. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants. Clin Toxicol. 2015;53:501-10. | Review | 2015-07 | |
| Caldirola D et al. Is there a role for pharmacogenetics in the treatment of panic disorder? Pharmacogenomics. 2015;16:771-4. | Editorial | 2015-07 | |
| Vandenberghe F et al. Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. Clin Pharmacokinet. 2015 Jul 1 [Epub ahead of print]. | PK | 2015-07 | |
| Winner JG et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a one year prospective evaluation. Curr Med Res Opin. 2015 July 23 [Epub ahead of print]. | Cost-effectiveness analysis | 2015-07 | |
| Chen R et al. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems. Eur J Clin Pharmacol. 2015;7:835-41. | PK/PD | 2015-07 | |
| Devlin AM et al. Metabolic side effects and pharmacogenetics of second-generation antipsychotics in children. Pharmacogenomics. 2015;16:981-6. | Review | 2015-06 | |
| Brennan FX et al. Naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim Care Companion CNS Disord. 2015;17(2). | Prospective Cohort | 2015-04 | |
| Van der Weide K et al. The Influence of the CYP3A4*22 polymorphism and CYP2D6 polymorphisms on serum concentrations of aripiprazole, haloperidol, pimozide, and risperidone in psychiatric patients. J Clin Psychopharmacol. 2015;35:228-36. | PK/PD | 2015-04 | |
| Helton SG et al. Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders. Pharmacogenomics. 2015;16:54153. | Review | 2015-04 | |
| Cabaleiro T et al. Pharmacogenetics of quetiapine in healthy volunteers: association with pharmacokinetics, pharmacodynamics, and adverse effects. Int Clin Psychopharmacol. 2015;30:82–8. | PK/PD | 2015-03 | |
| Hodgson K et al. Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology (Berl). 2015 Mar 12 [Epub ahead of print]. | cross-sectional | 2015-03 | |
| Kato M et al. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Transl Psychiatry. 2015;5:e513. | Retrospective analysis | 2015-02 | |
| Altar CA et al. Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenomics J. 2015 Feb 17 [Epub ahead of print]. | Retrospective analysis | 2015-02 | |
| Smith T et al. Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report. Int J Mol Sci. 2015;16:4416-28. | Case Report | 2015-02 | |
| Smith T et al. Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report. Int J Mol Sci. 2015;16:4416–28. | Case Report | 2015-02 | |
| Hamilton SP. The promise of psychiatric pharmacogenomics. Biol Psychiatry. 2015;77:2935. | Review | 2015-01 | |
| Dubovsky SL. The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression. Expert Opin Drug Metab Toxicol. 2015;111. | Expert opinion | 2015-01 | |
| Gardner KR et al. The potential utility of pharmacogenetic testing in psychiatry. Psychiatry J. 2014;2014:730956. | Review | 2014-12 | |
| Thompson C et al. Psychiatrist attitudes towards pharmacogenetic testing, direct-to-consumer genetic testing, and integrating genetic counseling into psychiatric patient care. Psychiatry Res. 2014 Dec 4 [Epub ahead of print]. | Cross sectional survey | 2014-12 | |
| Gassó P et al. Effect of CYP2D6, CYP2C9 and ABCB1 genotypes on fluoxetine plasma concentrations and clinical improvement in children and adolescent patients. Pharmacogenomics J. 2014;14:45762. | Prospective Cohort | 2014-11 | |
| Levy F. Applications of pharmacogenetics in children with attention-deficit/hyperactivity disorder. Pharmgenomics Pers Med. 2014;7:34956. | Review | 2014-11 | |
| Zhu AZX et al. Gene Variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes. Drug Metab Dispos. 2014;42:19717. | PK/PD Study | 2014-11 | |
| Ceskova E. The need to improve current psychopharmacotherapy before developing new drugs. Expert Opin Pharmacother. 2014;15:196973. | Editorial | 2014-11 | |
| Sicras-Mainar A et al. Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences. PLoS ONE. 2014;9:e90453. | Retrospective Cohort | 2014-11 | |
| Bowers K et al. Pharmacogenomic Medicine in Autism: Challenges and Opportunities. Paediatr Drugs. 2014 Nov 25 [Epub ahead of print]. | Review | 2014-11 | |
| Howland RH. Pharmacogenetic testing in psychiatry: not (quite) ready for primetime. J Psychosoc Nurs Ment Health Serv. 2014;52:136. | Perspective | 2014-11 | |
| Stevenson JM et al. Genetic determinants of selective serotonin reuptake inhibitor related sexual dysfunction. Pharmacogenomics. 2014;15:17911806. | Review | 2014-11 | |
| Chang FC et al. Clinical significance of pharmacogenomic studies in tardive dyskinesia associated with patients with psychiatric disorders. Pharmgenomics Pers Med. 2014;7:31728. | Review | 2014-10 | |
| Suzuki T et al. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and Its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit. 2014;36:6515. | PK/PD Study | 2014-10 | |
| Stingl J et al. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med. 2014 Oct 8 [Epub ahead of print]. | Review | 2014-10 | |
| Nussbaum LA et al. Molecular study of weight gain related to atypical antipsychotics: clinical implications of the CYP2D6 genotype. Rom J Morphol Embryol. 2014;55:87784. | Prospective Cohort | 2014-10 | |
| Tybura P et al. Pharmacogenetics of adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine. Psychiatry Res. 2014;219:2617. | Randomized trial | 2014-10 | |
| Garfield LD et al. Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial. Am J Geriatr Psychiatry. 2014;22:9719. | Randomized Clinical Trial | 2014-10 | |
| Youngster I et al. CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study. Dev Med Child Neurol. 2014;56:9904. | Retrospective Cohort Study | 2014-10 | |
| Chang M et al. Impact of Cytochrome P450 2C19 Polymorphisms on Citalopram/Escitalopram Exposure: A Systematic Review and Meta-Analysis. Clin Pharmacokinet. 2014;53:801-11. | Systematic review and meta-analysis | 2014-09 | Escitalopram, citalopram: Are higher doses needed in CYP2C19 ultrarapid metabolizers? |
| Zhu AZ et al. Gene Variants in CYP2C19 are Associated with Altered In Vivo Bupropion Pharmacokinetics but not Bupropion Assisted Smoking Cessation Outcomes. Drug Metab Dispos. 2014 Sep [Epub ahead of print]. | Pharmacokinetics and clinical study | 2014-09 | |
| Spina E et al. Clinical applications of CYP genotyping in psychiatry. Journal of Neural Transmission. 2014; [Epub ahead of print]. | Review | 2014-09 | |
| Fagerness J et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014;20:e14656. | Retrospective Cohort | 2014-09 | |
| Cabaleiro T et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Hum Psychopharmacol. 2014;29:45969. | PK | 2014-09 | |
| Bakken GV et al. Impact of genetic variability in CYP2D6, CYP3A5, and ABCB1 on serum concentrations of quetiapine and N-desalkylquetiapine in psychiatric patients. Ther Drug Monit. 2014 Sep [Epub ahead of print]. | Pharmacokinetic | 2014-09 | |
| Kumar Y et al. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation. J Psychopharmacol. 2014 Aug; [Epub ahead of print]. | Retrospective cohort | 2014-08 | |
| Waade RB et al. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J Clin Pharmacol. 2014;70:93340. | Retrospective cohort study
| 2014-08 | |
| Fabbri C et al. Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. Expert Opin Drug Metab Toxicol. 2014;10:1093-118. | Review | 2014-08 | |
| Cabaleiro T et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, andsafety of risperidone in healthy volunteers. Hum Psychopharmacol. 2014 Jul 9; [Epub ahead of print]. | Pharmacokinetic, pharmacodynamic | 2014-07 | |
| Tybura P et al. Pharmacogenetics of adverse events in schizophrenia treatment: Comparison study of ziprasidone, olanzapine and perazine. Psychiatry Research. 2014;219:261-7. | Prospective cohort study | 2014-06 | |
| Plesnicar BK et al. Therapeutic drug monitoring and pharmacogenetics--is this a way towards creative psychopharmacotherapy? Psychiatria Danubina. 2014;26:9699. | Review | 2014-06 | |
| Salloum NC et al. Towards the clinical implementation of pharmacogenetics in bipolar disorder. BMC Med. 2014;12:90. | Review | 2014-05 | |
| Lanktree MB et al. Positive perception of pharmacogenetic testing for psychotropic medications. Hum Psychopharmacol. 2014;29:287-91. | Survey | 2014-05 | |
| Brandl EJ et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. Pharmacogenomics J. 2014;14:176-81. | Prospective cohort | 2014-04 | CYP2D6 and CYP2C19 variability: Increased antidepressant trials, side effects? |
| Drozda K et al. Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options. Pharmacotherapy. 2014;34:16684. | Review | 2014-02 | |
